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Patients with rheumatoid arthritis (RA) are at greater risk of major cardiovascular (CV) events, 
predominantly due to accelerated atherosclerosis, underpinned by inflammation and RA-
disease factors, and also heart failure [1].  Overall modest event rate has necessitated the use 
of surrogate CV abnormalities of increased CV risk including arterial stiffness. Increased arterial 
stiffness is well-recognised in established RA [2], with early, similar reports using 
comprehensive and reliable cardiac magnetic resonance imaging (CMR) in our treatment-naïve, 
early onset RA cohort [3].  Autopsy, histopathological and clinical studies in general population 
and RA cohorts with and without CVD suggest citrullinated proteins as a mechanism for 
atherosclerosis, including presence of citrullination within the atherosclerotic plaque of 
subjects without RA [4, 5]. We hypothesised that individuals with circulating anti-CCP but no 
systemic inflammation (of RA typically associated with increased CV risk) also demonstrate CV 
abnormalities.
Anti-CCP positive individuals with any new musculoskeletal (MSK) symptoms but no clinical 
synovitis (subsequently termed at-risk individuals), and no prior history of CVD, were recruited 
from a tertiary centre Rheumatology outpatient clinic.  Following informed consent, 18 at-risk 
individuals and 30 healthy controls (HC) matched for age and gender, underwent multi-
parametric 3.0T CMR with late Gadolinium enhancement (Achieva, Philips, Best, The 
Netherlands) in an academic CMR centre.  As part of our previously described cohort studies at 
at-risk individuals were classified as low (<50%) or high (>50%) risk of developing RA using a 
published clinical risk model [6] and followed up for 12 months to assess for progression to a 
clinical diagnosis of RA. CMR analysis was performed blinded to patient details.  Using SPSS 
version 22, unpaired Student t-tests and Mann-Whitney tests compared continuous variables.
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Of the at-risk individuals, 4 (22%) were male, the mean (±SD) age was 53 ±15 years, anti-CCP 
136 ±136IU/ml and predicted absolute risk of RA 49 ±17%.  There were no differences between 
at-risk individuals and HC for age, gender, blood pressure, CV risk factors (hypertension, 
diabetes, hypercholesterolaemia) and active smoking status, although at-risk individuals had a 
higher body mass index (29 ±5 and 25 ±5 kg/m2 respectively) and proportion of ex-smokers 
(56% and 17% respectively).  Table S1 details baseline demographic data of at-risk RA 
individuals and HC. Five of the 18 recruited patients progressed to RA over 12 months.
Analyses (table 1) revealed aortic distensibility was notably lower (indicating greater arterial 
stiffness) in at-risk individuals compared with HC (3.6 ±1.3 versus 4.9 ±2.1 x 10-3mmHg-1 
respectively); a finding most pronounced in the high-risk individuals (n=8) compared to low-risk 
(n=10) (3.1 ±0.6 and 4.2 ±1. x 10-3mmHg-1 respectively), and in those who progressed to RA over 
12 months (see Table 1).  Similarly, sizeable differences in all other measures of aortic stiffness, 
including aortic compliance and aortic strain and aortic stiffness -Q.)& observed, again with 
greater aortic stiffness in high versus low at-risk individuals and in at-risk individuals progressing 
to RA. 
To our knowledge this is the first study showing subclinical increase in aortic stiffness in at-risk 
individuals for RA, with values numerically close to those seen in early, treatment naïve RA.  
Our use of CMR as a research tool offers a particularly sensitive assessment of structural and 
functional changes to reflect micro- and macro-vascular pathological processes of RA. The key 
limitation of this pilot study is absence of control groups. Nevertheless, the abnormal aortic 
stiffness measures were most pronounced in the high at-risk cohort and those progressing to 
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RA (albeit with a trend for greater stiffness also seen in low risk patients), implying a particular 
role of CCP antibodies.
These data advance the concept of anti-CCP mediated atherosclerosis and support additional 
investigation in larger, and both anti-CCP positive and negative control populations.  
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Table 1: Baseline CMR findings for at-risk individuals and healthy controls. 
Variable Healthy 
Controls 
(n=30)
All At-Risk 
Individuals 
(n=18)
P value 
(controls 
vs all at 
risk)
<50% At-Risk 
Individuals 
(n=8)
P value 
(controls 
vs <50% 
risk)
>50% At-Risk 
Individuals 
(n=10)
P value 
(controls 
vs >50% 
risk)
Progressors to 
RA within 1 
year (n=5)
P value 
(controls vs. 
progressors)
Non- 
progressors 
to RA within 
1 year 
(n=13)
P value 
(controls vs 
non- 
progressors)
Aortic stiffness
Aortic 
distensibility 
(10-3mmHg-1)
4.9 ± 2.1 3.6 ± 1.3 0.001 4.2 ± 1.7 0.35 3.1 ± 0.6 0.001 3.2 ± 0.7 0.002 3.8 ± 1.5 0.048
Aortic 
compliance
17.4 ± 4.2 14.3 ± 3.6 0.15 15.2 ± 3.5 0.15 13.6 ± 3.8 0.15 13.8 ± 5.1 0.20 14.5 ± 3.1 0.017
Aortic strain 0.25 ± 
0.08
0.20 ± 0.05 0.001 0.21 ± 0.08 0.23 0.19 ± 0.02 0.001 0.18 ± 0.02 0.001 0.21 ± 0.06 0.05
Aortic stiffness 
index -Q.
2.7 ± 0.9 3.4 ± 0.9 0.005 3.1 ± 1.0 0.29 3.7 ± 0.8 0.005 4.0 ± 1.1 0.048 3.2 ± 0.7 0.06
LV structure
LV Mass/BSA 
(g/m2)
49 ± 8 46 ± 10 0.72 44 ± 7 0.16 48 ± 11 0.72 45 ± 13 0.57 46 ± 9 0.39
Measures of 
fibrosis
Native T1 (ms) 1199 ± 35 1212 ± 34 0.39 1214 ± 40 0.37 1210 ± 32 0.39 1200 ± 21 0.98 1217 ± 38 0.19
ECV (%) 25.4 ± 2.5 27.7 ± 3.6 0.16 28.0 ± 3.7 0.1 27.4 ± 3.8 0.16 26.3 ± 1.7 0.35 28.3 ± 4.1 0.04
LGE 0/30 1/18 0.59 0/8 - 1/10 (10%) 0.59 0/5 - 1/13 (8%) 0.68
Function
S(seconds -1) 1.16 ± 
0.14
1.12 ± 0.12 0.23 1.16 ± 0.08 0.92 1.10 ± 0.14 0.23 1.12 ± 0.17 0.67 1.12 ± 0.10 0.31
LVEF (%) 62 ± 5 62 ± 4 0.95 61 ± 4 0.48 62 ± 4 0.95 63 ± 5 0.84 61 ± 4 0.49
LVEDV/BSA 
(ml/m2)
78 ± 10 83 ± 12 0.42 84 ± 9 0.17 83 ± 15 0.42 80 ± 16 0.88 84 ± 11 0.11
Torsion 
(degrees)
15.1 ± -
4.7
16.3 ± 4.6 0.76 17.1 ± 4.6 0.39 15.7 ± 4.8 0.76 13.7 ± 3.5 0.44 17.6 ± 4.7 0.19
Twist (degrees) 15.8 ± 4.6 17.1 ± 4.8 0.43 16.9 ± 5.2 0.66 17.3 ± 4.9 0.43 17.6 ± 5.5 0.53 16.9 ± 4.8 0.54
Mean (± SD) values presented unless otherwise stated.  
Page 8 of 25
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
Confidential: For Review Only
BSA, body surface area; ECV, extracellular volume; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LGE, late gadolinium 
enhancement
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